| Marked inhibition of growth and invasive parameters of head and neck squamous carcinoma FaDu by a nutrient mixture. | |
| | |
MedLine Citation:
|
PMID: 19679626 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Head and neck squamous cell carcinomas (HNSCCs) are known for their aggressive growth and propensity to metastasize. The authors investigated the effect of a novel nutrient mixture (NM) containing ascorbic acid, lysine, proline, and green tea extract on human HNSCC cell line FaDu in vivo and in vitro. Athymic male nude mice (n = 12) were inoculated with 3 x 10(6) FaDu cells subcutaneously and randomly divided into 2 groups: group A was fed a regular diet and group B a regular diet supplemented with 0.5% NM. Four weeks later, the mice were sacrificed and their tumors were excised, weighted, and processed for histology. In vitro, FaDu cells were cultured in Dulbecco's modified Eagle's medium and exposed to NM at 0 to 1000 microg/mL in triplicate. Cell proliferation was assessed by MTT assay, matrix metalloproteinase (MMP) secretion by gelatinase zymography, invasion through Matrigel, apoptosis by live-green caspases, and cell morphology by hematoxylin-eosin staining. NM inhibited the growth of tumors by 55% (P = .0002) and exhibited dose-dependent toxicity on FaDu cells in vitro, with 53% (P = .0003) at 1000 microg/mL NM. Zymography revealed MMP-2 and phorbol 12-myristate 13-acetate-induced MMP-9 secretion. NM inhibited secretion of both MMPs in a dose-dependent manner, with virtual total inhibition at 1000 microg/mL. NM significantly inhibited FaDu invasion through Matrigel with total block at 1000 microg/mL. NM induced dose-dependent apoptosis. In conclusion, NM has therapeutic potential in the treatment of HNSCC by significantly suppressing tumor growth and significantly inhibiting MMP secretion and invasion of HNSCC cells in vitro. |
| | |
Authors:
|
M W Roomi; N W Roomi; T Kalinovsky; M Rath; A Niedzwiecki |
Related Documents
:
|
16150786 - Circulating endothelial cells in relapse and limited granulomatous disease due to anca ... 3481336 - Effect of daunorubicin, carminomycin, idarubicin and 4-demethoxydaunorubicinol against ... 10348746 - Molecular investigation of the postantibiotic effects of clarithromycin and erythromyci... 11306136 - Inhibition of egg hatching success and larvae survival of the scallop, chlamys farreri,... 8224246 - Differentiation of hl60 promyelocytic cells is promoted by a 'differentiation enhancing... 10849096 - Merkel cell tumour with leiomyosarcomatous differentiation. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Integrative cancer therapies Volume: 8 ISSN: 1534-7354 ISO Abbreviation: Integr Cancer Ther Publication Date: 2009 Jun |
Date Detail:
|
Created Date: 2009-08-14 Completed Date: 2009-09-29 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101128834 Medline TA: Integr Cancer Ther Country: United States |
Other Details:
|
Languages: eng Pagination: 168-76 Citation Subset: IM |
Affiliation:
|
Dr Rath Research Institute, Oncology Division, Santa Clara, California 95050, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Administration, Oral Amino Acids / administration & dosage, pharmacology, therapeutic use Animals Apoptosis / drug effects Ascorbic Acid / administration & dosage, analogs & derivatives, pharmacology, therapeutic use Camellia sinensis / chemistry Carcinoma, Squamous Cell / drug therapy*, metabolism, pathology Cell Line, Tumor Cell Survival / drug effects Complementary Therapies / methods* Food* Head and Neck Neoplasms / drug therapy*, metabolism, pathology Humans Male Matrix Metalloproteinase 2 / metabolism Matrix Metalloproteinase 9 / metabolism Mice Mice, Nude Neoplasm Invasiveness Plant Extracts / administration & dosage, pharmacology, therapeutic use Tetradecanoylphorbol Acetate / pharmacology Xenograft Model Antitumor Assays |
| Chemical | |
Reg. No./Substance:
|
0/Amino Acids; 0/Plant Extracts; 16561-29-8/Tetradecanoylphorbol Acetate; 50-81-7/Ascorbic Acid; EC 3.4.24.24/Matrix Metalloproteinase 2; EC 3.4.24.35/Matrix Metalloproteinase 9 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: An Alternative Treatment for Cervical Intraepithelial Neoplasia II, III.
Next Document: Potency of Andrographolide as an Antitumor Compound in BHC-Induced Liver Damage.